Casopitant

Casopitant
	220px
Systematic (IUPAC) name
	(2S,4S)-4-(4-Acetyl-1-piperazinyl)-N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-1-piperidinecarboxamide
Identifiers
ATC code	A04AD13 (WHO)
PubChem	CID 23725089
Chemical data
Formula	C30H35F7N4O2
Molar mass	616.26 g/mol[[Script error: No such module "String".]]
	Script error: No such module "collapsible list".

Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Casopitant (trade names Rezonic (US), Zunrisa (EU)) is an neurokinin 1 (NK₁) receptor antagonist undergoing research for the treatment of chemotherapy-induced nausea and vomiting (CINV).^[1] It is currently under development by GlaxoSmithKline (GSK).

In July 2008, the company filed a marketing authorisation application with the European Medicines Agency. The application was withdrawn in September 2009 because GSK decided that further safety assessment was necessary.^[2]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

45px	This drug article relating to the gastrointestinal system is a stub. You can help ssf by expanding it. v d e

35px	This drug article relating to the nervous system is a stub. You can help ssf by expanding it. v d e

↑ Lohr L (2008). "Chemotherapy-induced nausea and vomiting". Cancer J. 14 (2): 85–93. doi:10.1097/PPO.0b013e31816a0f07. PMID 18391612.
↑ "GlaxoSmithKline withdraws its marketing authorisation application for Zunrisa" (PDF). London: EMEA. 13 October 2009. Retrieved 21 December 2009.

[1] Lohr L (2008). "Chemotherapy-induced nausea and vomiting". Cancer J. 14 (2): 85–93. doi:10.1097/PPO.0b013e31816a0f07. PMID 18391612.

[2] "GlaxoSmithKline withdraws its marketing authorisation application for Zunrisa" (PDF). London: EMEA. 13 October 2009. Retrieved 21 December 2009.

[1]

[2]

Casopitant

See also

References

Navigation menu

Views

Personal tools

Navigation

Search

Tools

adverts